NovaBridge selects 8 mg/kg dose for givastomig and reports strong Phase 1b results
NovaBridge Biosciences presented updated Phase 1b data for givastomig in first‑line metastatic gastroesophageal adenocarcinoma at ESMO 2026. The 8 mg/kg dose showed a 79% objective response rate and a 16.9‑month median progression‑free survival. The company announced alignment with the FDA on a global Phase 3 protocol and will host a webcast on 2 Nov 2026 to discuss registrational plans.
Why it matters
The company says the mature data and dose selection provide a clear pathway to a registrational Phase 3 trial, which could drive future revenue if the drug receives approval. Investors should watch for the upcoming webcast for details on the Phase 3 design and timelines.
Key facts
- 1Objective response rate at the 8 mg/kg dose was 79% (23/29). stocktitan.net
- 2Disease control rate at the 8 mg/kg dose was 97% (28/29). stocktitan.net
- 3Median duration of response was 15.2 months. stocktitan.net
- 4Median progression‑free survival was 16.9 months. stocktitan.net
- 5Median follow‑up for the 8 mg/kg cohort was 17.8 months. stocktitan.net
- 6NovaBridge selected the 8 mg/kg dose for registrational development. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.